MedTrace Logo

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

NCT05335447 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-06-30

No results posted yet for this study

Summary

This is a study in healthy male volunteers to assess how a new test medicine is taken up and broken down by the body as well as its safety and tolerability.

Conditions

  • Healthy

Interventions

DRUG

GLPG3667 capsule

On Day 1, participants will receive a single oral dose of GLPG3667

DRUG

[14C]-GLPG3667 solution for infusion

On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion

DRUG

[14C]-GLPG3667 capsule

On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Galapagos Study Director, MD · Galapagos NV

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2022-06-03
Completion
2022-06-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335447 on ClinicalTrials.gov